Clément F
Schweiz Med Wochenschr. 1983 Jun 11;113(23):838-43.
Serum beta 2 microglobulin (beta 2 mu) level was determined in 157 patients followed up for 1 to 38 months. In 42 patients with nonremissional lymphoproliferative malignancies, the observed values (mean 4.35 +/- 2.24 mg/l) were much higher than the beta 2 mu levels obtained either in the 37 healthy subjects (mean 1.86 +/- 0.30 mg/l) or in the 39 patients with various nonmalignant diseases (mean 2.68 +/- 1.76 mg/l). However, for diagnostic purposes serum beta 2 mu level determination is still of very limited value: if the beta 2 mu level is below 2.50 mg/l, the beginning of a hematologic malignancy cannot be excluded; beta 2 mu levels between 2.50 and 5.00 mg/l are observed, in most cases, with lymphoproliferative or myeloproliferative disorders, but these values are also often found in various diseases, particularly of viral or autoimmunological etiology; a serum beta 2 mu level above 5.00 mg/l was obtained only in lymphoproliferative malignancies and in one case of "acquired immuno deficiency syndrome" (AIDS) in a homosexual male. Serum beta 2 mu determination is of chief advantage in follow-up of Hodgkin's disease, of non-Hodgkin malignant lymphoma, of chronic lymphocytic leukemia and of multiple myeloma either during treatment or in remission.
对157例随访1至38个月的患者测定了血清β2微球蛋白(β2μ)水平。在42例未缓解的淋巴增殖性恶性肿瘤患者中,观察值(平均4.35±2.24mg/L)远高于37名健康受试者(平均1.86±0.30mg/L)或39例患有各种非恶性疾病的患者(平均2.68±1.76mg/L)的β2μ水平。然而,就诊断目的而言,血清β2μ水平测定的价值仍然非常有限:如果β2μ水平低于2.50mg/L,不能排除血液系统恶性肿瘤的开始;在大多数情况下,β2μ水平在2.50至5.00mg/L之间见于淋巴增殖性或骨髓增殖性疾病,但这些值也常见于各种疾病,特别是病毒或自身免疫病因的疾病;仅在淋巴增殖性恶性肿瘤患者以及一名同性恋男性的“获得性免疫缺陷综合征”(AIDS)患者中获得了高于5.00mg/L的血清β2μ水平。血清β2μ测定在霍奇金病、非霍奇金恶性淋巴瘤、慢性淋巴细胞白血病和多发性骨髓瘤的治疗期间或缓解期的随访中具有主要优势。